Indian Journal of Medical Research

REVIEW ARTICLE
Year
: 2019  |  Volume : 150  |  Issue : 3  |  Page : 221--227

Anti-thymocyte globulin in haematology: Recent developments


Salahuddin Siddiqui1, Jessica Cox2, Roger Herzig1, Senthilnathan Palaniyandi1, Gerhard C Hildebrandt1, Reinhold Munker1 
1 Department of Medicine (Hematology & BMT), University of Kentucky, Lexington, KY, USA
2 College of Pharmacy, Lexington, KY, USA

Correspondence Address:
Dr Reinhold Munker
Department of Medicine (Hematology & BMT), University of Kentucky, Lexington, KY 40536
USA

Anti-thymocyte globulin (ATG) is a polyclonal antiserum introduced into clinical medicine more than 30 years ago. It induces a broad non-specific immunosuppression. In haematology, standard indications are severe aplastic anaemia and prophylaxis and treatment of graft-versus-host disease (GVHD) (after allogeneic transplantation). For aplastic anaemia, ATG from horses has been found to be superior to ATG from rabbits. In the situation of allogeneic transplantation, ATG lessens the risk of chronic GVHD but may not improve survival. There is current controversy regarding which patients benefit most from ATG and what the ideal dosage is. It is likely that in the coming years a more specific immunosuppressive will be developed that will minimize GVHD while maintaining the graft-versus-malignancy effect.


How to cite this article:
Siddiqui S, Cox J, Herzig R, Palaniyandi S, Hildebrandt GC, Munker R. Anti-thymocyte globulin in haematology: Recent developments.Indian J Med Res 2019;150:221-227


How to cite this URL:
Siddiqui S, Cox J, Herzig R, Palaniyandi S, Hildebrandt GC, Munker R. Anti-thymocyte globulin in haematology: Recent developments. Indian J Med Res [serial online] 2019 [cited 2019 Nov 22 ];150:221-227
Available from: http://www.ijmr.org.in/article.asp?issn=0971-5916;year=2019;volume=150;issue=3;spage=221;epage=227;aulast=Siddiqui;type=0